bispecific agents: the future of aml and mds treatment?
Published 6 years ago • 85 plays • Length 1:02Download video MP4
Download video MP3
Similar videos
-
2:26
insights into the future of aml therapy: the increasing use of targeted agents
-
1:28
cd47 antibodies for the treatment of aml and mds: where is the field moving?
-
2:43
novel therapies in the future of mds treatment
-
1:04
the future of mds management
-
2:56
the exciting future of bispecific antibodies
-
2:16
current and future treatment approaches for hr-mds
-
2:02
unmet needs in high-risk mds and future therapeutic strategies
-
1:54
fusion-aml-001: molecular changes associated with azacitidine & durvalumab in tp53m aml and hr-mds
-
43:38
webinar - bispecific antibodies: the next generation of antibody therapeutics
-
31:06
a new vis app for automated immune infiltrate analysis with multispectrally unmixed images
-
4:48
managing and treating mds
-
2:09
advances in the management of fit adults with aml
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo
-
1:32
the importance of cytogenetics and molecular profiling for accurate aml/mds diagnosis
-
2:50
phase i study of abbv383, a novel bcmaxcd3 bispecific antibody, in r/r multiple myeloma
-
1:21
future treatment priorities for high-risk mds
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
2:33
what can artificial intelligence bring to the diagnosis and management of mds?
-
1:33
sequencing and the management of adverse events when administering bispecifics for myeloma
-
2:22
outcomes and management of patients with r/r myeloma who progress on bispecific antibodies
-
5:06
personalized therapy for mds: advancements and the future
-
3:24
novel agents in higher-risk mds